Abbott Laboratories $ABT Shares Acquired by Janney Montgomery Scott LLC

Posted by Brian Himes on Jun 29th, 2026

Janney Montgomery Scott LLC increased its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 8.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 665,144 shares of the healthcare product maker’s stock after purchasing an additional 52,945 shares during the period. Janney Montgomery Scott LLC’s holdings in Abbott Laboratories were worth $68,290,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Freemont Management S.A. raised its holdings in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories in the fourth quarter valued at $116,580,000. Thrivent Financial for Lutherans increased its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after buying an additional 48,286 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth $185,640,000. Finally, Net Worth Advisory Group acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $1,366,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $94.02 on Monday. The stock has a market capitalization of $163.77 billion, a P/E ratio of 26.34, a P/E/G ratio of 1.62 and a beta of 0.63. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm’s 50-day moving average is $89.08 and its two-hundred day moving average is $105.27.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the firm posted $1.09 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Analysts Set New Price Targets

ABT has been the topic of a number of research reports. Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Argus reduced their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. JPMorgan Chase & Co. lowered their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Bank of America reduced their target price on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $118.30.

View Our Latest Stock Analysis on ABT

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.